ClinicalTrials.gov
public full text
Public Domain
Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer
The purpose of the study is to evaluate the efficacy and toxicity of apatinib in patients with platinum resistant or refractory ovarian cancer when combined with etoposide.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Apatinib With Albumin-bound Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer#913140
- SGI-110 in Combination With Carboplatin in Ovarian Cancer#839915
- Clinical Study of Apatinib in the Treatment of Platinum Resistant Recurrent Ovarian Cancer#893627
- Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer#898491
- Weekly Paclitaxel With or Without Pazopanib in Platinum Resistant or Refractory Ovarian Cancer#1044191
Record · ID 832483
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive